Telink Pharmaceutical (01011.HK) rose by 250%. The company announced that it is considering issuing letter shares to four creditors to capitalize the outstanding principal amount and interest of the existing loans owed by the group to subscribers.
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.